The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Phase Ib/II study of sonrotoclax with carfilzomib & dexamethasone in t(11;14) RRMM
Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, The University of Melbourne, Melbourne, Australia, discusses the initial results of a Phase Ib/II study (NCT04973605) investigating sonrotoclax in combination with carfilzomib and dexamethasone in patients with t(11;14) relapsed/refractory multiple myeloma (RRMM). She highlights the favorable safety profile and encouraging efficacy results. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
